Abstract: A system for detecting and classifying a wheel of a rail vehicle traveling on a railway track includes a plurality of wheel detectors coupled to one rail of the railway track and configured to detect presence of the wheel and to generate signals representative thereof. A processing system is coupled to the wheel detectors and configured to receive and process the signals. The processing system is configured to classify the wheel based on a speed independent classification value calculated based on the signals from the wheel detectors.

Abstract: A system for detecting and classifying a wheel of a rail vehicle traveling on a railway track includes a plurality of wheel detectors coupled to one rail of the railway track and configured to detect presence of the wheel and to generate signals representative thereof. A processing system is coupled to the wheel detectors and configured to receive and process the signals. The processing system is configured to classify the wheel based on a speed independent classification value calculated based on the signals from the wheel detectors.

Abstract: Methods and pharmaceutical compositions of use in regulation of mammalian bone-forming activities of SFRPs (secreted frizzled-related proteins) are disclosed. SFRPs are secreted receptors for Wnts, which are important polypeptide growth factors that are known to regulate fundamental biological processes such as tissue polarity, embryonic development, and tumorigenesis. Methods can be used to identify compounds which target the Wnt-antagonizing function of an SFRP by way of one or more domains or specific amino acids. Pharmaceutical compositions can be prepared using these compounds, and bone disorders can be treated using these pharmaceutical compositions.

Abstract: The present invention relates to a Wnt-Frizzled chimera. The present invention also relates to pharmaceutical compositions that can be screened or developed using Wnt-Frizzled chimeras. The methods and pharmaceutical compositions of the present invention can be used to treat bone disorders and cancer.

Abstract: The present invention provides isolated nucleic acids encoding full-length human estrogen receptor-? (hER?), which comprises 530 amino acids. The invention also provides isolated hER? polypeptides and hER?-reactive antibodies, including those that specifically recognize amino acids 1-45 of hER?. The invention also encompasses methods for identifying hER?-interactive compounds, including agonists, antagonists, and co-activators.